Teva's Eltrombopag Olamine ANDA209938 Receives Approval
Teva Pharmaceuticals has received approval for their ANDA209938 application for Eltrombopag Olamine.
Published: July 18, 2026
Updated: July 18, 2026
Author: Humanexa Intelligence
Therapeutic area: Hematology / Thrombocytopenia
Company: Teva
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Teva
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Teva's approval for Eltrombopag Olamine introduces a new competitor in the thrombocytopenia market, which could disrupt pricing and market share dynamics. Portfolio teams must evaluate the implications for their existing products and prepare for potential competitive responses.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and any subsequent competitive responses from other manufacturers.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.